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Abstract
Background: In South Africa, drug resistant tuberculosis is a major public health crisis in the face of the colossal
HIV pandemic.
Methods: In an attempt to understand the distribution of drug resistance in our setting, we analysed the rpoB,
katG, inhA, pncA and embB genes associated with resistance to key drugs used in the treatment of tuberculosis in
clinical isolates of Mycobacterium tuberculosis in the KwaZulu-Natal province.
Results: Classical mutations were detected in the katG, inhA and embB genes associated with resistance to isoniazid
and ethambutol. Diverse mutations were recorded in the multidrug resistant (MDR) and extensively drug resistant
(XDR) isolates for the rpoB and pncA gene associated with resistance to rifampicin and pyrazinamide.
Conclusions: M.tuberculosis strains circulating in our setting display a combination of previously observed mutations,
each mediating resistance to a different drug. The MDR and XDR TB isolates analysed in this study displayed classical
mutations linked to INH and EMB resistance, whilst diverse mutations were linked to RIF and PZA resistance. The similarity
of the XDR strains confirms reports of the clonality of the XDR epidemic. The successful dissemination of the drug
resistant strains in the province underscores the need for rapid diagnostics to effectively diagnose drug resistance and
guide treatment.
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Background
Tuberculosis (TB) remains one of the greatest public
health concerns of our time, exacerbated by drug-
resistant strains of Mycobcterium tuberculosis and co-
infection with human immunodeficiency virus (HIV). In
its latest global TB report in 2015, the world health
organization (WHO) estimated that 3.5 % of new cases
and 20.5 % previously treated patients have multi-drug
resistant (MDR) TB; i.e. resistance to isoniazid (INH)
and rifampicin (RIF). Of these cases, 9 % have exten-
sively drug resistant (XDR) TB. XDR TB strains display
resistance to INH, RIF and additional resistance to a
fluoroquinolone antibiotic and one of the three inject-
able second line agents: amikacin (AMIK), kanamycin
(KAN) and capreomycin (CAP) [1].
Despite the implementation of therapeutic regimes
combining INH, RIF, ethambutol (EMB) and pyrazina-
mide (PZA) [2], the escalation of MDR strains has
compromised the utility of this drug combination.
The morbidity and mortality rates associated with
drug resistant TB is several times higher than with
drug susceptible forms [1]. Treatment of drug resist-
ant TB is further complicated by the decreased effi-
cacy and higher toxicity associated with the second
line drugs as well as the inability to provide early
diagnostic data to guide treatment [3]. Conventional
drug susceptibility testing relies on mycobacterial
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culture methods, providing results after weeks or
months. Despite remarkable strides made in advan-
cing diagnosis of drug-resistant TB with molecular-
based diagnostics, such as the GeneXpert MTB/RIF
assay, this technology currently only detects reistance
to RIF [4].
The most common genes associated with resistance
to the first-line drugs in M.tuberculosis have been iden-
tified based on the mode of action of each of the drugs
and their demonstrated association with drug resist-
ance. These include ropB (RIF), katG and inhA (INH),
pncA (PZA) and embB (EMB). The clinical relevance of
these mutations have been amply discussed [5, 6]. The
recent application of whole genome sequencing has
provided in-dept insight on the development and evo-
lution of drug resistance, including the complexity of
resistance in M.tuberculosis. Interestingly, over a hun-
dered genetic loci implicated in drug resistance. A re-
cent study identified mutations in fourty genes linked
to INH resistance, highlighting the dynamic evolution
of resistance-conferring mutations under drug pressure.
Furthermore, muations associated with drug resistance
play varying roles, which include causative or com-
pensatory mutations or may result in increased fitness
[3, 7]. Cohen et al. demonstrated that M.tuberculosis
isolates bearing the most prevalent RIF resistance mu-
tation (rpoB S450L), were most likely to have to
compensatory mechanisms to overcome fitness costs
associated with the mutation [8]. In addition to this
complexity, resistance-conferring mutations in
M.tuberculoisis vary geographically and according to
the strain type [3].
In the study described in this report, we analysed muta-
tions in the ropB, katG, inhA, pncA and embB genes and
their association to resistance to the key first-line antimi-
crobials in clinical isolates from the KwaZulu-Natal
province of South Africa.
Methods
M. tuberculosis clinical isolates
M. tuberculosis clinical isolates were selected from the
storage collection of the Infection Control laboratory,
University of KwaZulu-Natal. The isolates were from
sputum specimens obtained from patients presenting
to the Church of Scotland Hospital in the Tugella Ferry
region of KZN, South Africa from 2005 to 2009. At ini-
tial isolation, the drug susceptibility profiles of the iso-
lates were established in our laboratory using the 1 %
proportion method [9]. Sixty isolates were selected for
the study: 10 drug susceptible (DS), 15 multi-drug re-
sistant (MDR-TB) and 28 extensively drug resistant
(XDR-TB). The H37Rv laboratory strain was included
as a control.
Determination of the Minimum Inhibitory Concentration
(MIC)
MIC was established using a multipoint inoculation
technique on Middlebrook 7H10 agar medium supple-
mented with oleic acid-albumin-dextrose-catalase
(OADC). Test plates contained INH, RIF and EMB at
concentrations of 0.125; 0.25; 0.5; 1; 2; 4; 8; 16; 32; 64
and 128 mg/L. The plates were seeded with an M.tuber-
culosis suspension matched to spectrophotometer ab-
sorbance reading of 1 at a wavelenght of 600 nm. Test
plates were incubated at 37 °C for 21 days in the pres-
ence of 5 % CO2. The MIC of an isolate was recorded as
the lowest antibiotic concentration that inhibited growth
of the organism. Resistance to INH, RIF and EMB was
defined as concentrations of 0.2, 1.0 and 5.0 mg/L re-
spectively, in accordance to WHO guidelines [10]. Iso-
lates were tested in triplicate to ensure test accuracy and
reproducibility. Due to the technical difficulty associated
with conducting PZA testing in an acid based medium,
MIC’s for the drug was not conducted.
Genomic DNA extraction & amplification
Genomic DNA was extracted from cultures grown on
Middlebrook 7H11 media using the CTAB-NaCl
(Cetyl-trimethyl-ammonium Bromide-Sodium Chlor-
ide) method, as described previously [11]. The integrity
and concentration of the DNA was determined using a
NanoDrop 2000c spectrophotometer (Thermo Scien-
tific). PCR amplification assays were carried out for the
inhA, katG, rpoB, pncA and embB genes. Primers for
each of the genes were selected from published litera-
ture or designed using Primer3 design software [12].
The Expand Hi Fidelity PCR kit (Roche) was used in
accordance to the guidelines set out by the manufac-
turer. Table 1 contains specific annealing temperatures
and primer sequences used for amplification.
DNA sequencing & analysis
Prior to sequencing, the quality of PCR amplicons were
determined on a 1 % agarose gel. Amplicons were puri-
fied using the Invitrogen PureLink PCR purification kit
(Applied Biosystems) and sequenced using ABI Prism
Big Dye Terminator cycle sequencing kit V3.1 (Applied
Biosystems) together with the forward primers selected
for PCR amplification. Nucleotide sequences were
aligned to the H37Rv reference strain using Genious
V5.5.7 (Biomatters) sequence analysis software [13].
Genotyping
The genotypes of the isolates were established using the
IS6110 restriction fragment length polymorphism (RFLP)
method, as described previously [14].
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Results
RFLP analysis
RFLP analysis revealed that most of the DS isolates
belonged to the Beijing family of strains. Three DS iso-
lates had a unique profile and 1 isolate was a variant of
the F11 strain family. The F28 strain family was the pre-
dominant genotype of the MDR isolates, whereas the
remaining isolates belonged to the F15/LAM4/KZN
(KZN) strain family. One MDR isolate recorded a
unique profile and 1 was a variant of the F28 strain fam-
ily. All of the XDR isolates analysed in the study
belonged to the KZN strain family. Genotypes, muta-
tions and associated phenotypes are shown in Tables 2,
3 and 4.
rpoB mutations and RIF resistance
Majority (73 %) of the RIF resistant isolates had at least
1 mutation in the rpoB gene, while 5 RIF resistant (3
MDR, 2 XDR) isolates had no alteration within the rpoB
gene. The rpoB mutations were of various types: (1)
A→G substitution in codon 435 (A1304G, D435G); de-
tected in 5 XDR isolates with an MIC range of 64–
128 mg/L, belonging to the KZN family of strains (2).
T→C substitution in codon 452 (T1355C, L452P); de-
tected in 1 MDR isolate of the KZN family strain family
with an MIC of 8 mg/L (3). C→T substitution in codon
450 (C1349T, S450L); detected in 6 MDR isolates which
belonged to the KZN and F28 strain families with an
MIC range of 32–128 mg/L. Double mutants included
(4) C→T substitution in codon 435 (C1303T, D435Y)
together with an C→A substitution in codon 454
(C1360A, P454T); detected in 1 MDR isolate of the
KZN strain family with an MIC of 128 mg/L (5). A→T
substitution in codon 445 (A1334T, H445L) and a G→
C substitution in codon 491 (G1473C, I491M); detected
in 1 MDR isolate, a variant of the F28 strain family with
an MIC of 128 mg/L (6). The S450L and L452P detected
in 2 MDR isolates of the KZN and F28 strain families
with an MIC of 64 mg/L; (7) the D435G and L452P de-
tected in 21 XDR isolates belonging to the KZN strain
family with an MIC range of 32–128 mg/L (8). The
S450L and a T→C substitution in codon 564 (T1690C,
Y564H), detected in 2 MDR isolates of the KZN strain
family with an MIC of 128 mg/L. No mutations were de-
tected in any of the DS isolates screened.
inhA; katG mutations and INH resistance
No mutations were detected in the inhA gene or its pro-
moter region amongst the isolates screened in the study.
The katGmutations were of 3 types (1). G→T substitution
in codon 473 (G1388T; no amino acid alteration); detected
in 5 DS isolates, all belonging to the Beijing family of strains
(2). G→C substitution in codon 315 (G944C, S315T); de-
tected in all of the MDR and XDR isolates studied. The
MIC range of the isolates was 4–16 mg/L. The mutation
was detected across all genotypes detected in the study (3).
Table 1 Primer sequences and annealing temperatures used for PCR and sequencing
Gene Primer Nucleotide Sequence
(5′→ 3′)
Annealing Temp (°C) Associated Drug Resistance Ref
rpoB rpoB F TGTTGGACATCTACCGCAAG 54 °C Rifampicin *
rpoB R CGAGACGTCCATGTAGTCCA
inhA inhA F CTACATCGACACCGATATGAC 55 °C Isoniazid [26]
inhA R GACCGTCATCCAGTTGTAG
katG katG F GGTCGACATTCGCGAGACGTT 57 °C Isoniazid [27]
katG R TTGTTCCTGCGACGCATCGTG
pncA pncA F GCTGGTCATGTTCGCGATCG 59 °C Pyrazinamide [28]
pncA R GCTTTGCGGCGAGCGCTCCA
embB embB F AAGCTGGCGCACCTTCAC 55 °C Ethambutol *
embB R ATAGCGCGGTGATCAAAAA
* newly designed primers
Table 2 Mutations in the rpoB, katG, pncA and embB genes
with the associated MICs and genotypes of the drug susceptible
isolates
Isolate Genotype MIC (mg/L) Mutation Profile
RIF INH EMB rpoB katG pncA embB
TF1538 Unique 1 ≤0.125 2 - - - -
TF1413 Beijing 1 16 2 - G1388T - -
TF1582 Beijing 1 ≤0.125 2 - G1388T - -
TF832 F11V 1 ≤0.125 2 - - - -
TF1519 Beijing 1 ≤0.125 2 - - - -
TF1001 Unique 1 ≤0.125 2 - - - -
TF933 Unique 1 ≤0.125 2 - - - -
P090811 Beijing 1 ≤0.125 2 - G1388T - -
P090802 Beijing 1 ≤0.125 2 - G1388T - -
P090804 Beijing 1 ≤0.125 2 - G1388T - -
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One MDR isolate, unique in its genotype had double muta-
tions within the katG gene. In addition to the S315T muta-
tion, an A→C substitution in codon 468 (A1343C,
N468A) was detected, associated with MIC of 16 mg/L.
The remaining DS isolates had no alteration in the
katG gene.
pncA mutations and PZA resistance
pncA gene mutations were of 3 types (1). T→G substi-
tution in codon 34 (T100G, Y34D); detected in 6 MDR
isolates, 5 of which belonged to the F28 family and the
remaining isolate belonged to the KZN family of strains
(2). T→G substitution in codon 139 (T416G, L139G);
detected in 2 MDR isolates, belonging to the KZN family
of strains (3). Insertion of a cytosine at position 457,
present in 1 MDR and all the XDR isolates screened, all
belonging to the KZN strain family, resulting in a frame-
shift. The remaining MDR isolates and DS isolates had
no alteration in the pncA gene.
embB mutations and EMB resistance
The embB mutations were of 2 types (1). A→G substi-
tution in codon 306 (A916G, M306V); detected in 9
MDR and all the XDR isolates, associated with an MIC
range of 2–16 mg/L. The mutation was detected across
all genotypes of the study (2). C→A substitution in
codon 506 (C1489A, Q506K); detected in 2 MDR iso-
lates, belonging to the F28 family of strains and associ-
ated with an MIC of 16 mg/L. The remaining MDR and
DS isolates had no alteration in the emB gene.
Mutations of the rpoB, inhA, katG, embB and pncA
genes, MIC’s and associated genotypes are shown in Ta-
bles 2, 3 and 4.
Discussion
In this study, we report on the mechanisms mediating
first-line drug resistance amongst clinical isolates from
KwaZulu-Natal, South Africa. South Africa ranks
amongst the top ten high burden countries of drug re-
sistant tuberculosis worldwide. The overall incidence
rate in the KwaZulu-Natal province alone currently ex-
ceeds the incidence rates for all types of TB in some low
incidence countries, like the USA [15]. In an attempt to
understand the molecular basis of first-line drug resist-
ance in our setting, we sequenced the ropB, inhA, katG,
pncA and embB genes associated with resistance to key
drugs used in the treatment of DS tuberculosis.
Table 3 Mutations in the rpoB, katG, pncA and embB genes with the associated MICs and genotypes of the MDR isolates
Isolate Genotype MIC (mg/L) Mutation Profile
aAssociated amino acid substitutions
RIF INH EMB rpoB katG pncA embB
MODS11 KZN 8 8 8 T1355C G944C ΔC A916G
MODS688 KZN 128 8 8 C1349T
T1690C
G944C T416G A916G
TF44949 F28 32 16 8 C1349T G944C - A916G
TF3251 KZN 128 16 16 G1303T
C1360A
G944C - A916G
TF78838 F28 128 16 8 C1349T G944C T100G A916G
TF2063 F28 128 16 16 C1349T G944C T100G A916G
TF3203 F28 128 16 16 C1349T G944C T100G A916G
TF1951 F28V 128 16 16 A1334T
G1473C
G944C - A916G
TF64747 KZN 128 16 8 C1349T
T1690C
G944C T416G A916G
TF2889 F28 64 16 8 C1349T
T1355C
G944C - C1489A
TF2040 F28 128 16 16 C1349T G944C T100G C1489A
MODS682 F28 128 16 16 - G944C - -
TF36480 KZN 128 16 8 - G944C T100G -





TF2153 F28 128 16 16 - G944C T100G -
arpoB: C1303T = D435Y; A1334T = H445L; C1349T = S450L; T1355C = L452P; C1360A = P454T; G1473C = I491M; T1690C = Y564H
katG: G944C = S315T
pncA: ΔC = Insertion of cytosine at position 457; T100G = Y34D; T416G = L139G
embB: A916G =M306V; C1489A = Q506K
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Analysis of the inhA, katG and embB genes demon-
strated classical mechanisms that have been associated
with resistance to INH and EMB [5, 6]. No mutations
were detected in the inhA gene or its promoter region in
the isolates screened. This is in keeping with previous
reports [16]. Common inhA mutations that have been
reported occur in the inhA promoter region at position
−15, its correlation, however, is strongest with INH
mono-resistant isolates or isolates with low-level INH
resistance [5, 6]. A recent study demonstrated that
double mutations in the inhA gene, in the promoter and
coding regions, resulted in high-level INH resistance
[17]. A large number of RIF resistant isolates bear
mutations in the inhA and its promoter region making
these mutations high predictors of RIF resistance, des-
pite being absent in a subset of INH resistant isolates.
The main mechanism mediating INH resistance in the
isolates studied is the katG S315T mutation that was de-
tected in all the MDR and XDR isolates. Numerous re-
ports have found this mutation to be the most common
mutation associated with INH resistance. One MDR iso-
late with unique genotype had double mutations in the
inhA gene:the S315T mutation occurred in conjunction
with the N468A mutation. The double mutant did not
record a higher MIC as compared to the other isolates
bearing the S315T mutation only. The N468A appears
Table 4 Mutations in the rpoB, katG, pncA and embB genes with the associated MICs and genotypes of the XDR isolates
Isolate Genotype MIC (mg/L) Mutation Profile
aAssociated amino acid substitutions
RIF INH EMB rpoB katG pncA embB
TF1762 KZN 16 8 16 A1304G T1355C G944C ΔC A916G
MODS141 KZN 128 8 16 A1304G T1355C G944C ΔC A916G
MODS39 KZN 32 4 2 A1304G T1355C G944C ΔC A916G
MODS387 KZN 128 16 8 A1304G T1355C G944C ΔC A916G
MODS338 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
MODS667 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
MODS513 KZN 128 8 16 A1304G T1355C G944C ΔC A916G
MODS143 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF1824 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF1925 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF66937 KZN 128 16 8 A1304G T1355C G944C ΔC A916G
TF80198 KZN 128 16 8 A1304G T1355C G944C ΔC A916G
TF80164 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF1497 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF75549 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF31066 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF739 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
MODS370 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF3181 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF37806 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
TF2981 KZN 128 16 16 A1304G T1355C G944C ΔC A916G
MODS334 KZN 128 16 16 - - G944C ΔC A916G
TF2038 KZN 128 16 16 A1304G - G944C ΔC A916G
TF3228 KZN 128 16 16 - - G944C ΔC A916G
TF25027 KZN 128 16 8 A1304G - G944C ΔC A916G
TF51648 KZN 128 16 16 A1304G - G944C ΔC A916G
TF49127 KZN 64 16 16 A1304G - G944C ΔC A916G
MODS 195 KZN 32 16 8 A1304G - G944C ΔC A916G
arpoB:A1304G = D435G; T1355C = L452P
katG: G944C = S315T
pncA: ΔC = Insertion of cytosine at position 457
embB: A916G =M306V; C1489A = Q506K
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to be novel, but may represent a natural polymorphism
or phylogenetic marker of the unique genotype of the
isolate. The G1388T mutation detected in the 5 DS iso-
lates is natural polymorphism associated with the Beijing
genotype that has no bearing on resistance.
Approximately 96 % of RIF resistance is attributed to
mutations contained in an 81 bp hot-spot region known
as the RIF resistance determining region (RRDR) which
encompasses codons 507–533 of the rpoB gene [5, 6].
Mechanisms of resistance for the MDR and XDR isolates
varied in the case of RIF resistance, despite the MICs
falling within a similar range. Various mutation types
were described amongst the MDR isolates. The S450L
(corresponding to codon 531 in E.coli) mutation was the
most common, accounting for resistance in 7 MDR iso-
lates, in keeping with various reports. Four MDR Isolates
had the S450L mutation together with L452P (corre-
sponding to codon 533 in E.coli) or the T564H mutation
[16]. One MDR isolate had the L452P mutation only.
One isolate had the H445L (corresponding to codon 526
in E.coli) and the I491M mutation [16]. To the best of
our knowledge, the I491M and T564H mutations are
novel and appear to be involved in mediating RIF
resistance.
The main mutation mediating RIF resistance in the
XDR isolates was the D435G mutation together with the
L452P mutation. This was detected in all the XDR iso-
lates and 1 MDR isolate. Three isolates had the D435G
mutation only and one isolate had the S450L mutation.
Although the mutations and genotypes of the isolates
were diverse, all mutations correlated with high level
RIF resistance. Interestingly, the MDR and XDR isolates
both had mutations in codon 435 but each resulted in
different amino acid substitutions. Similar findings were
described for KZN MDR and XDR isolates in a study by
Ioger et al. [16] analysing the whole genome sequences
of drug resistant isolates KZN strain family. The main
mechanism mediating resistance in the KZN MDR iso-
late was attributed to the D435Y mutation and the
D435G and L452P mutations in the KZN XDR isolates.
The study only analysed the KZN strain family [16]. Our
study shows a greater diversity in the MDR RIF resist-
ance mechanisms and the isolates represented various
strain families. In our study, the mutation in codon 435
was responsible for resistance in most of the MDR iso-
lates. In contrast, Ioger et al. reported that this mutation
was only responsible for 9 % of RIF resistance [16].
Resistance to PZA, as in the case of RIF was repre-
sented by diverse mutations in the MDR and XDR iso-
lates. The MDR isolates had a mutation either in codon
34 (nucleotide 100) or codon 139 nucleotide 416), while
XDR isolates had an insertion of a cytosine at position
457, leading to a frameshift in the amino acid transla-
tion. The insertion was also detected in one MDR
isolate, possibly with a higher level of resistance to PZA.
Due to technical difficulty associated with PZA suscepti-
bility testing, no MICs were carried out for the drug. In-
stead, we sought to identify mutations in the MDR and
XDR groups and compare them with published litera-
ture. Mutations at position 100 have been described in
isolates in Japan and Peru while mutations at position
416 have been reported South Africa, Thailand, China,
USA, Portugal, Spain and Singapore [18–26]. The inser-
tion at position 457 has been described in isolates from
Brazil [27].
Mutations within the pncA gene are highly diverse,
with 600 unique mutations at 400 different positions re-
ported to date [28]. In keeping with this diversity, the
study by Ioger et al. showed different mechanisms of
PZA resistance in the MDR and XDR isolates from the
KZN strain family as compared to the mechanisms de-
scribed in this report [14]. This highlights the difficulty
associated with detection of PZA resistance. The diver-
sity of the mutations detected in the isolates varies
greatly, making it impossible to apply to molecular diag-
nostic assay. PZA susceptibility testing poses a further
challenge. The PZase enzyme required for the conver-
sion of PZA to its active form is only functional at an
acid pH, making it difficult to test the drug using con-
ventional media. With a prevalence of approximately
60.5 % in patients with confirmed MDR TB, PZA resist-
ance testing is of utmost importance as PZA forms an
integral role in current multidrug regimens and is also a
key component of new treatment regimens undergoing
evaluation in phase II or III clinical trials [29, 30].
A few isolates resistant to RIF and PZA did not display
any mutations in the related genes. This phenomena has
been previously described [5, 6]. This suggests that alter-
nate resistance mechanisms may exist that remain to be
identified. The differences in resistance mechanisms in
the MDR and XDR isolates suggest that the strains
emerged separately and acquired resistance mutations
independently. This is against the premise that the XDR
phenotype had evolved directly from the MDR pheno-
type, consistent with previous reports [14].
Conclusion
In conclusion, we demonstrate that the M.tuberculosis
strains circulating in our setting display a combination
of previously observed mutations, each mediating
resistance to a different drug. The MDR and XDR TB
isolates analysed in this study displayed classical muta-
tions linked to INH and EMB resistance, whilst diverse
mutations were linked to RIF and PZA resistance. The
observation that all XDR-TB isolates appear identical
(KZN strain) is consistent with reports endemic trans-
mission of XDR-TB in our region. This strain is highly
virulent and has displayed increased fitness despite the
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burden of carrying resistance conferring mutations
[31]. The results of the study underscores the need for
rapid drug susceptibility testing to improve treatment
efficacy and subsequent treatment outcomes. Future
studies are required to determine that factors that drive
the dynamic evolution of M.tuberculosis drug resistance
under antibiotic pressure in patients over time. Whilst
various new developments offer a ray of hope, these are
years away from integration into TB programmes. Thus
strengthening of public health systems and the strin-
gent antibiotic stewardship remain critical in TB con-
trol efforts.
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